The newly diagnosed patients with epithelial ovarian cancer, primary peritoneal cancer or fallopian tube cancer.
Conditions
Interventions
None listed
Sponsors
AstraZeneca K.K.
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: 1.The subject can attach the signature to the Informed Consent Form (ICF), besides having her intention to put the signature. 2.Female Japanese at more than 20 years of age 3.The newly diagnosed patients whose epithelial ovarian cancer, primary peritoneal cancer or fallopian tube cancer is histologically confirmed as FIGOs Stage I to Stage IV. However, diagnosis should be based on the histopathological diagnosis on the surgically resected tumor specimens (except the cytodiagnosis by ascites paracentesis). 4.The histopathological specimens can be submitted to the central pathological judgment. 5.Within 60 days after diagnosis of epithelial ovarian cancer, primary peritoneal cancer or fallopian tube cancer, the patients written consent has been obtained.
Exclusion criteria
Exclusion criteria: 1.In case of the subjects who are diagnosed to have acute or chronic physical or severe mental diseases except cancer, and about whom the attending responsible physician makes judgement to say that participation of these subjects would possibly increase the risks or would probably disturb the interpretation of the study results. 2.In case of the subjects whose registration for the study is judged by the attending responsible physician as inappropriate.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary objectives of this study are to investigate the ownership ratio of gBRCAm in the newly diagnosed patients with epithelial ovarian cancer, primary peritoneal cancer or fallopian tube cancer, which has been inadequately clarified in Japan so far. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1.Ownership ratio of gBRCAm when stratified according to the patients demographics 2.Evaluation of the satisfaction levels of the patients toward explanation about the BRCA genetic testing | — |
Countries
Japan
Contacts
Public ContactMitsuru Shimomura
CMIC HOLDINGS Co., Ltd. BIU
Outcome results
None listed